Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

NCT ID: NCT01279798

Last Updated: 2011-03-01

Basic Information

• Recruitment Status: NO_LONGER_AVAILABLE
• Study Classification: EXPANDED_ACCESS

Brief Summary

This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03. A total of 45 patients will be enrolled into the study.

Detailed Description

The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.

The secondary objectives of this study are:

• Evaluate the best overall tumor response.
• Evaluate progression-free survival (PFS).
• Evaluate treatment toxicity.

Conditions

Non-small Cell Lung Cancer

Interventions

Lucanix® (belagenpumatucel-L)

Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.

Intervention Type: BIOLOGICAL

Other Intervention Names

Lucanix

Eligibility Criteria

Inclusion Criteria

• Signed informed consent
• ≥ 18 years
• Histological confirmed non-curable stage III or IV NSCLC.
• Must have completed at least one (1) regimen of anti-cancer therapy.
• Following frontline therapy, subjects must observe the following wash- out periods:

• Subjects with stable disease or better must have received the last anti-cancer therapy not less than five months prior to enrollment.
• Subjects with progressive disease must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
• All subjects who have received two (2) or more regimens of therapy must have received the last anti-cancer therapy at least one (1) month prior to enrollment.
• Performance status (ECOG) ≤ 2
• Absolute granulocyte count ≥ 1,500/mm3
• Platelet count ≥ 100,000/mm3
• Total Bilirubin ≤ 2× Upper Limit of Normal
• AST and ALT ≤ 2× Upper Limit of Normal
• Creatinine ≤ 2× Upper Limit of Normal
• Negative pregnancy test for women of childbearing potential.

Exclusion Criteria

• Concurrent systemic steroids > 2 mg prednisone/day
• Prior splenectomy
• Any chemotherapy, steroid therapy, or investigational anti-cancer agent within 4 weeks of study entry.
• Subjects who received prior monotherapy with Lucanix.
• Symptomatic brain metastases unless treated and stable for ≥ 2 months
• Known HIV positivity
• Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.
• Prior malignancy (excluding non-melanoma carcinomas of the skin) unless in remission for ≥ 2 years
• History of psychiatric disorder that would impede adherence to protocol
• Pregnant or nursing women or refusal to practice contraception if of reproductive potential

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NovaRx Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

NovaRx Corporation

Locations

Innovative Research Center of California

San Diego, California, United States

Countries

United States

References

Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10;24(29):4721-30. doi: 10.1200/JCO.2005.05.5335. Epub 2006 Sep 11.

Reference Type: RESULT

PMID: 16966690 (View on PubMed)

Related Links

http://www.novarx.com/

NovaRx Website

Other Identifiers

NR001-04

Identifier Type: -

Identifier Source: org_study_id